This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ito, D. Articles by Fukuuchi, Y. Search for Related Content PubMed PubMed Citation Articles by Ito, D. Articles by Fukuuchi, Y. Related Collections Risk Factors Genetics of Stroke Risk Factors for Stroke Mechanism of atherosclerosis/growth factors

(Stroke. 2000;31:2661.)
© 2000 American Heart Association, Inc.

Original Contributions

Polymorphism in the Promoter of Lipopolysaccharide Receptor CD14 and Ischemic Cerebrovascular Disease

Daisuke Ito, MD; Mitsuru Murata, MD; Norio Tanahashi, MD; Hideki Sato, MD; Akira Sonoda, BS; Ikuo Saito, MD; Kiyoaki Watanabe, MD Yasuo Fukuuchi, MD

From the Departments of Neurology (D.I., N.T., H.S., Y.F.), Laboratory Medicine (M.M., A.S., K.W.), Hematology (M.M.), and Health Center (I.S.), School of Medicine, Keio University, Tokyo, Japan.

Correspondence to Daisuke Ito, MD, Department of Neurology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Background and Purpose—A growing amount of evidence suggests that infectious and inflammatory processes may be involved in the initiation of arteriosclerosis, but the mechanisms are conceivably multifactorial and complex. Two European groups have recently demonstrated that a C(-260)T polymorphism in the promoter of the CD14 lipopolysaccharide receptor may be a risk factor for coronary artery disease (CAD). The T allele of this polymorphism reportedly increases the expression of CD14 and may be involved in atherogenesis. In the present study we investigated a possible association between the C(-260)T polymorphism in the CD14 promoter and the occurrence of symptomatic ischemic cerebrovascular disease (CVD).

Methods—Genotype frequencies of the C(-260)T polymorphism in the CD14 promoter were determined in 235 patients with CVD, as confirmed by brain CT and/or MRI, and 309 age- and sex-matched control subjects.

Results—The distribution of genotypes was as follows: CVD patients, T/T 24.3%, C/T 53.2%, and C/C 22.6%; controls, T/T 26.9%, C/T 50.2%, and C/C 23.0%. There was no significant difference between the CD14 promoter genotypes of the CVD patients and the controls (²=0.601, P=0.741). We also measured the concentration of serum soluble CD14 and the density of membranous CD14 on monocytes in the CVD patients, but the polymorphism was not associated with either the concentration of soluble CD14 or the density of membranous CD14 (P=0.358, P=0.238, respectively).

Conclusions—Our results indicate that the C(-260)T polymorphism in the CD14 promoter is not associated with an increased risk for CVD.

Key Words: lipopolysaccharides • polymorphism (genetics) • risk factors • stroke

This article has been cited by other articles:

				C. Hermann Review: Variability of host pathogen interaction Innate Immunity, August 1, 2007; 13(4): 199 - 218. [Abstract] [PDF]

				A. Simpson, S. L. John, F. Jury, R. Niven, A. Woodcock, W. E. R. Ollier, and A. Custovic Endotoxin Exposure, CD14, and Allergic Disease: An Interaction between Genes and the Environment Am. J. Respir. Crit. Care Med., August 15, 2006; 174(4): 386 - 392. [Abstract] [Full Text] [PDF]

				S. von Aulock, J. Rupp, K. Gueinzius, M. Maass, and C. Hermann Critical Investigation of the CD14 Promoter Polymorphism: Lack of a Role for In Vitro Cytokine Response and Membrane CD14 Expression Clin. Vaccine Immunol., October 1, 2005; 12(10): 1254 - 1256. [Abstract] [Full Text] [PDF]

				B. OSTERUD and E. BJORKLID Role of Monocytes in Atherogenesis Physiol Rev, October 1, 2003; 83(4): 1069 - 1112. [Abstract] [Full Text] [PDF]

				P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]

				J. F. Meschia Addressing the Heterogeneity of the Ischemic Stroke Phenotype in Human Genetics Research Stroke, December 1, 2002; 33(12): 2770 - 2774. [Abstract] [Full Text] [PDF]

				W. Koenig, N. Khuseyinova, M. M. Hoffmann, W. Marz, M. Frohlich, A. Hoffmeister, H. Brenner, and D. Rothenbacher CD14 C(-260)->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease J. Am. Coll. Cardiol., July 3, 2002; 40(1): 34 - 42. [Abstract] [Full Text] [PDF]

				R. Y.L. Zee, D. Bates, and P. M. Ridker A Prospective Evaluation of the CD14 and CD18 Gene Polymorphisms and Risk of Stroke Stroke, April 1, 2002; 33(4): 892 - 895. [Abstract] [Full Text] [PDF]

				D Ito, N Tanahashi, M Murata, H Sato, I Saito, K Watanabe, and Y Fukuuchi Notch3 gene polymorphism and ischaemic cerebrovascular disease J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 382 - 384. [Abstract] [Full Text] [PDF]